EGFR and neoplasm: Antibodies are also widely used for nanocarrier functionalization based on their inherent capability to specifically recognize their targets, and the promising results of cetuximab and panitumumab administration in improving clinical outcomes for mCRC patients lead to the use of these molecules as functionalization agents to direct nanoparticles towards tumor cells that overexpress EGFR.